이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NVN Liquidation 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Scott Plesha

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	1.6yrs
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

CEO

Scott Plesha (58 yo)

less than a year

테뉴어

Mr. Scott M. Plesha is Chief Executive Officer of Ligand Pharmaceuticals Incorporated from April 2024. Mr. Plesha had been the President of BioDelivery Sciences International, Inc. since December 2017 and...

리더십 팀

이름	위치	테뉴어	보상	소유권
John Gay	Chief Financial Officer	5.3yrs	US$568.23k	0.17% $ 0.05
Scott Plesha	CEO & Director	less than a year	데이터 없음	데이터 없음
Carri Geer	Senior VP & CTO	5.3yrs	데이터 없음	데이터 없음
Sai Rangarao	Senior VP	less than a year	데이터 없음	데이터 없음
Tomoko Maeda-Chubachi	Chief Medical Officer	2.8yrs	데이터 없음	데이터 없음
Melvin Whitehead	Senior Vice President of Manufacturing Operations	less than a year	데이터 없음	데이터 없음

1.6yrs

평균 재임 기간

경험이 풍부한 관리: 0A4P 의 관리팀은 경험 (평균 재직 기간 1.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

NVN Liquidation 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.71 loss in 1Q 2022)

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.74 loss in FY 2021)

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Forecast to breakeven in 2025

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.39 loss in 2Q 2021)

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

First quarter 2022 earnings released: US$0.71 loss per share (vs US$0.60 loss in 1Q 2021)

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.63 loss in 3Q 2020)

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

CEO

테뉴어

리더십 팀

평균 재임 기간